Larimar Therapeutics Statistics
Total Valuation
LRMR has a market cap or net worth of $382.04 million. The enterprise value is $185.44 million.
Important Dates
The next estimated earnings date is Thursday, August 13, 2026, before market open.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
LRMR has 104.38 million shares outstanding. The number of shares has increased by 24.53% in one year.
| Current Share Class | 103.88M |
| Shares Outstanding | 104.38M |
| Shares Change (YoY) | +24.53% |
| Shares Change (QoQ) | +5.96% |
| Owned by Insiders (%) | 1.12% |
| Owned by Institutions (%) | 43.49% |
| Float | 59.99M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.42 |
| P/TBV Ratio | 2.42 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.29, with a Debt / Equity ratio of 0.02.
| Current Ratio | 4.29 |
| Quick Ratio | 4.21 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -109.83% and return on invested capital (ROIC) is -69.31%.
| Return on Equity (ROE) | -109.83% |
| Return on Assets (ROA) | -56.92% |
| Return on Invested Capital (ROIC) | -69.31% |
| Return on Capital Employed (ROCE) | -107.26% |
| Weighted Average Cost of Capital (WACC) | 8.66% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.34M |
| Employee Count | 71 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +12.62% in the last 52 weeks. The beta is 0.82, so LRMR's price volatility has been lower than the market average.
| Beta (5Y) | 0.82 |
| 52-Week Price Change | +12.62% |
| 50-Day Moving Average | 3.82 |
| 200-Day Moving Average | 3.98 |
| Relative Strength Index (RSI) | 51.94 |
| Average Volume (20 Days) | 2,347,876 |
Short Selling Information
The latest short interest is 10.54 million, so 10.09% of the outstanding shares have been sold short.
| Short Interest | 10.54M |
| Short Previous Month | 8.05M |
| Short % of Shares Out | 10.09% |
| Short % of Float | 17.56% |
| Short Ratio (days to cover) | 4.50 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -172.43M |
| Pretax Income | -166.01M |
| Net Income | -166.01M |
| EBITDA | -172.10M |
| EBIT | -172.43M |
| Earnings Per Share (EPS) | -$2.09 |
Full Income StatementBalance Sheet
The company has $200.39 million in cash and $3.78 million in debt, giving a net cash position of $196.61 million or $1.88 per share.
| Cash & Cash Equivalents | 200.39M |
| Total Debt | 3.78M |
| Net Cash | 196.61M |
| Net Cash Per Share | $1.88 |
| Equity (Book Value) | 158.03M |
| Book Value Per Share | 1.51 |
| Working Capital | 157.22M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$131.28 million and capital expenditures -$42,000, giving a free cash flow of -$131.32 million.
| Operating Cash Flow | -131.28M |
| Capital Expenditures | -42,000 |
| Depreciation & Amortization | 326,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -131.32M |
| FCF Per Share | -$1.26 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |